ZBED5

Across TCGA pan-cancer cohorts, ZBED5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZBED5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZBED5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBED5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where ZBED5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.697	.005	6	view →
LSCC	OS	Median	All	1.000	0.940	.017	5	view →
UCEC	DFS	Median	II,III,IV	0.502	0.856	.034	4	view →
HNSC	OS	Tertile	III,IV	0.432	0.858	.031	2	view →
PDAC	DFS	Tertile	All	0.194	0.441	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZBED5–CCRCC (DFS)

Open the CCRCC breakdown →